Targeted Chemotherapy in Bone and Soft-Tissue Sarcoma

Orthopedic Clinics of North America

Volumn 46, Issue 4, 2015, Pages 587-608

  Harwood, Jared L ^a   Alexander, John H ^a   Mayerson, Joel L ^a   Scharschmidt, Thomas J ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

Bone; Chemotherapy; Sarcoma; Targeted; Tumor

Indexed keywords

BEVACIZUMAB; CIXUTUMUMAB; CRIZOTINIB; EVEROLIMUS; EZRIN; GANITUMAB; IMATINIB; INTERLEUKIN 11 RECEPTOR ALPHA; MAMMALIAN TARGET OF RAPAMYCIN; NOTCH RECEPTOR; PALBOCICLIB; PAZOPANIB; PROTEIN BCL 2; PROTEIN P53; PROTEIN TYROSINE KINASE; RETINOBLASTOMA PROTEIN; RIDAFOROLIMUS; SCATTER FACTOR RECEPTOR; SOMATOMEDIN; SONIC HEDGEHOG PROTEIN; SORAFENIB; STAT3 PROTEIN; TEMSIROLIMUS; TRABECTEDIN; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR RUNX; TRASTUZUMAB; VASCULOTROPIN; WNT PROTEIN; ANTINEOPLASTIC AGENT;

ANGIOSARCOMA; CANCER CELL DESTRUCTION; CANCER CHEMOTHERAPY; CANCER GENETICS; CANCER PROGNOSIS; CANCER SURVIVAL; CARCINOGENESIS; CHONDROSARCOMA; DERMATOFIBROSARCOMA PROTUBERANS; DRUG EFFICACY; EWING SARCOMA; HUMAN; LUNG ALVEOLUS CELL CARCINOMA; METASTASIS; OSTEOSARCOMA; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; RHABDOMYOSARCOMA; SARCOMA; SIGNAL TRANSDUCTION; SOFT TISSUE SARCOMA; SURVIVAL RATE; SURVIVAL TIME; BONE NEOPLASMS; GENETICS; MOLECULARLY TARGETED THERAPY; SOFT TISSUE NEOPLASMS;

ANTINEOPLASTIC AGENTS; BONE NEOPLASMS; CARCINOGENESIS; HUMANS; MOLECULAR TARGETED THERAPY; SARCOMA; SOFT TISSUE NEOPLASMS;

EID: 84942196627     PISSN: 00305898     EISSN: 15581373     Source Type: Journal    
DOI: 10.1016/j.ocl.2015.06.011     Document Type: Review

References (199)

1. Link M.P., Goorin A.M., Miser A.W., et al. The effect of adjuvant chemotherapy on relapse-free survival in patients with osteosarcoma of the extremity. N Engl J Med 1986, 314:1600-1606.
2. Eilber F., Giuliano A., Eckardt J., et al. Adjuvant chemotherapy for osteosarcoma: a randomized prospective trial. J Clin Oncol 1987, 5:21-26.
3. Bernthal N.M., Federman N., Eilber F.R., et al. Long-term results (>25 years) of a randomized, prospective clinical trial evaluating chemotherapy in patients with high-grade, operable osteosarcoma. Cancer 2012, 118:5888-5893.
4. Bramwell V.H., Burgers M., Sneath R., et al. A comparison of two short intensive adjuvant chemotherapy regimens in operable osteosarcoma of limbs in children and young adults: the first study of the European Osteosarcoma Intergroup. J Clin Oncol 1992, 10:1579-1591.
5. Souhami R.L., Craft A.W., Van der Eijken J.W., et al. Randomised trial of two regimens of chemotherapy in operable osteosarcoma: a study of the European Osteosarcoma Intergroup. Lancet 1997, 350:911-917.
6. Lewis I.J., Nooij M.A., Whelan J., et al. Improvement in histologic response but not survival in osteosarcoma patients treated with intensified chemotherapy: a randomized phase III trial of the European Osteosarcoma Intergroup. J Natl Cancer Inst 2007, 99:112-128.
7. Le Deley M.C., Guinebretière J.M., Gentet J.C., et al. SFOP OS94: a randomised trial comparing preoperative high-dose methotrexate plus doxorubicin to high-dose methotrexate plus etoposide and ifosfamide in osteosarcoma patients. Eur J Cancer 2007, 43:752-761.
8. Collins M., Wilhelm M., Conyers R., et al. Benefits and adverse events in younger versus older patients receiving neoadjuvant chemotherapy for osteosarcoma: findings from a meta-analysis. J Clin Oncol 2013, 31:2303-2312.
9. Bacci G., Picci P., Ruggieri P., et al. Primary chemotherapy and delayed surgery (neoadjuvant chemotherapy) for osteosarcoma of the extremities. The Istituto Rizzoli experience in 127 patients treated preoperatively with intravenous methotrexate (high versus moderate doses) and intraarterial cisplatin. Cancer 1990, 65:2539-2553.
10. Ferrari S., Ruggieri P., Cefalo G., et al. Neoadjuvant chemotherapy with methotrexate, cisplatin, and doxorubicin with or without ifosfamide in nonmetastatic osteosarcoma of the extremity: an Italian sarcoma group trial ISG/OS-1. J Clin Oncol 2012, 30:2112-2118.
11. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Bone Cancer. Version 1. 2015. Available online at: Accessed 28 July, 2015. http://www.nccn.org/professionals/physician_gls/pdf/bone.pdf.
12. Bacci G., Briccoli A., Rocca M., et al. Neoadjuvant chemotherapy for osteosarcoma of the extremities with metastases at presentation: recent experience at the Rizzoli Institute in 57 patients treated with cisplatin, doxorubicin, and a high dose of methotrexate and ifosfamide. Ann Oncol 2003, 14:1126-1134.
13. Navid F., Willert J.R., McCarville M.B., et al. Combination of gemcitabine and docetaxel in the treatment of children and young adults with refractory bone sarcoma. Cancer 2008, 113:419-425.
14. Goorin A.M., Harris M.B., Bernstein M., et al. Phase II/III trial of etoposide and high-dose ifosfamide in newly diagnosed metastatic osteosarcoma: a pediatric oncology group trial. J Clin Oncol 2002, 20:426-433.
15. Berger M., Grignani G., Ferrari S., et al. Phase 2 trial of two courses of cyclophosphamide and etoposide for relapsed high-risk osteosarcoma patients. Cancer 2009, 115:2980-2987.
16. Esiashvili N., Goodman M., Marcus R.B.J. Changes in incidence and survival of Ewing sarcoma patients over the past 3 decades: Surveillance Epidemiology and End Results data. J Pediatr Hematol Oncol 2008, 30:425-430.
17. Herzog C.E. Overview of sarcomas in the adolescent and young adult population. J Pediatr Hematol Oncol 2005, 27:215-218.
18. Cotterill S.J., Ahrens S., Paulussen M., et al. Prognostic factors in Ewing's tumor of bone: analysis of 975 patients from the European Intergroup Cooperative Ewing's Sarcoma Study Group. J Clin Oncol 2000, 18:3108-3114.
19. Nesbit M.E.J., Gehan E.A., Burgert E.O., et al. Multimodal therapy for the management of primary, nonmetastatic Ewing's sarcoma of bone: a long-term follow-up of the First Intergroup study. J Clin Oncol 1990, 8:1664-1674.
20. Burgert E.O.J., Nesbit M.E., Garnsey L.A., et al. Multimodal therapy for the management of nonpelvic, localized Ewing's sarcoma of bone: intergroup study IESS-II. J Clin Oncol 1990, 8:1514-1524.
21. Evans R.G., Nesbit M.E., Gehan E.A., et al. Multimodal therapy for the management of localized Ewing's sarcoma of pelvic and sacral bones: a report from the second intergroup study. J Clin Oncol 1991, 9:1173-1180.
22. Paulussen M., Ahrens S., Dunst J., et al. Localized Ewing tumor of bone: final results of the cooperative Ewing's Sarcoma Study CESS 86. J Clin Oncol 2001, 19:1818-1829.
23. Grier H.E., Krailo M.D., Tarbell N.J., et al. Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone. N Engl J Med 2003, 348:694-701.
24. Maheshwari A.V., Cheng E.Y. Ewing sarcoma family of tumors. J Am Acad Orthop Surg 2010, 18:94-107.
25. Granowetter L., Womer R., Devidas M., et al. Dose-intensified compared with standard chemotherapy for nonmetastatic Ewing sarcoma family of tumors: a Children's Oncology Group Study. J Clin Oncol 2009, 27:2536-2541.
26. Womer R.B., West D.C., Krailo M.D., et al. Randomized controlled trial of interval-compressed chemotherapy for the treatment of localized Ewing sarcoma: a report from the Children's Oncology Group. J Clin Oncol 2012, 30:4148-4154.
27. Oberlin O., Patte C., Demeocq F., et al. The response to initial chemotherapy as a prognostic factor in localized Ewing's sarcoma. Eur J Cancer Clin Oncol 1985, 21:463-467.
28. Bacci G., Ferrari S., Bertoni F., et al. Prognostic factors in nonmetastatic Ewing's sarcoma of bone treated with adjuvant chemotherapy: analysis of 359 patients at the Istituto Ortopedico Rizzoli. J Clin Oncol 2000, 18:4-11.
29. Lin P.P., Jaffe N., Herzog C.E., et al. Chemotherapy response is an important predictor of local recurrence in Ewing sarcoma. Cancer 2007, 109:603-611.
30. Wunder J.S., Paulian G., Huvos A.G., et al. The histological response to chemotherapy as a predictor of the oncological outcome of operative treatment of Ewing sarcoma. J Bone Joint Surg Am 1998, 80:1020-1033.
31. Paulussen M., Ahrens S., Burdach S., et al. Primary metastatic (stage IV) Ewing tumor: survival analysis of 171 patients from the EICESS studies. European Intergroup Cooperative Ewing Sarcoma Studies. Ann Oncol 1998, 9:275-281.
32. Miser J.S., Krailo M.D., Tarbell N.J., et al. Treatment of metastatic Ewing's sarcoma or primitive neuroectodermal tumor of bone: evaluation of combination ifosfamide and etoposide-a Children's Cancer Group and Pediatric Oncology Group study. J Clin Oncol 2004, 22:2873-2876.
33. Magnan H., Goodbody C.M., Riedel E., et al. Ifosfamide dose-intensification for patients with metastatic Ewing sarcoma. Pediatr Blood Cancer 2015, 62(4):594-597.
34. Hamilton S.N., Carlson R., Hasan H., et al. Long-term outcomes and complications in pediatric Ewing sarcoma. Am J Clin Oncol 2015, [Epub ahead of print].
35. Gelderblom H., Hogendoorn P.C., Dijkstra S.D., et al. The clinical approach towards chondrosarcoma. Oncologist 2008, 13:320-329.
36. Patrikidou A., Domont J., Cioffi A., et al. Treating soft tissue sarcomas with adjuvant chemotherapy. Curr Treat Options Oncol 2011, 12:21-31.
37. Cormier J.N., Pollock R.E. Soft tissue sarcomas. CA Cancer J Clin 2004, 54:94-109.
38. Pisters P.W., Harrison L.B., Leung D.H., et al. Long-term results of a prospective randomized trial of adjuvant brachytherapy in soft tissue sarcoma. J Clin Oncol 1996, 14:859-868.
39. Yang J.C., Chang A.E., Baker A.R., et al. Randomized prospective study of the benefit of adjuvant radiation therapy in the treatment of soft tissue sarcomas of the extremity. J Clin Oncol 1998, 16:197-203.
40. Eilber F.C., Rosen G., Nelson S.D., et al. High-grade extremity soft tissue sarcomas: factors predictive of local recurrence and its effect on morbidity and mortality. Ann Surg 2003, 237:218-226.
41. Kang S., Kim H.S., Kim S., et al. Post-metastasis survival in extremity soft tissue sarcoma: a recursive partitioning analysis of prognostic factors. Eur J Cancer 2014, 50:1649-1656.
42. Adjuvant chemotherapy for localised resectable soft-tissue sarcoma of adults: meta-analysis of individual data. Sarcoma Meta-analysis Collaboration. Lancet 1997, 350:1647-1654.
43. Buesa J.M., López-Pousa A., Martín J., et al. Phase II trial of first-line high-dose ifosfamide in advanced soft tissue sarcomas of the adult: a study of the Spanish Group for Research on Sarcomas (GEIS). Ann Oncol 1998, 9:871-876.
44. Casali P.G., Blay J.Y. Soft tissue sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010, 21(Suppl 5):v198-v203.
45. Pervaiz N., Colterjohn N., Farrokhyar F., et al. A systematic meta-analysis of randomized controlled trials of adjuvant chemotherapy for localized resectable soft-tissue sarcoma. Cancer 2008, 113:573-581.
46. Penel N., Bui B.N., Bay J.O., et al. Phase II trial of weekly paclitaxel for unresectable angiosarcoma: the ANGIOTAX Study. J Clin Oncol 2008, 26:5269-5274.
47. Kollar A., Benson C. Current management options for liposarcoma and challenges for the future. Expert Rev Anticancer Ther 2014, 14:297-306.
48. Rosen G., Forscher C., Lowenbraun S., et al. Synovial sarcoma. Uniform response of metastases to high dose ifosfamide. Cancer 1994, 73:2506-2511.
49. Sleijfer S., Ouali M., van Glabbeke M., et al. Prognostic and predictive factors for outcome to first-line ifosfamide-containing chemotherapy for adult patients with advanced soft tissue sarcomas: an exploratory, retrospective analysis on large series from the European Organization for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (EORTC-STBSG). Eur J Cancer 2010, 46:72-83.
50. Leahy M., Garcia Del Muro X., Reichardt P., et al. Chemotherapy treatment patterns and clinical outcomes in patients with metastatic soft tissue sarcoma. The SArcoma treatment and Burden of Illness in North America and Europe (SABINE) study. Ann Oncol 2012, 23:2763-2770.
51. Hanahan D., Weinberg R.A. The hallmarks of cancer. Cell 2000, 100:57-70.
52. van Oosterom A.T., Judson I., Verweij J., et al. Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study. Lancet 2001, 358:1421-1423.
53. Waller C.F. Imatinib mesylate. Recent Results Cancer Res 2014, 201:1-25.
54. Cronin M., Ross J.S. Comprehensive next-generation cancer genome sequencing in the era of targeted therapy and personalized oncology. Biomark Med 2011, 5:293-305.
55. Roukos D.H., Ku C.S. Clinical cancer genome and precision medicine. Ann Surg Oncol 2012, 19:3646-3650.
56. Workman P., Al-Lazikani B., Clarke P.A. Genome-based cancer therapeutics: targets, kinase drug resistance and future strategies for precision oncology. Curr Opin Pharmacol 2013, 13:486-496.
57. Linch M., Miah A.B., Thway K., et al. Systemic treatment of soft-tissue sarcoma-gold standard and novel therapies. Nat Rev Clin Oncol 2014, 11:187-202.
58. Kansara M., Teng M.W., Smyth M.J., et al. Translational biology of osteosarcoma. Nat Rev Cancer 2014, 14:722-735.
59. Jo V.Y., Fletcher C.D. WHO classification of soft tissue tumours: an update based on the 2013 (4th) edition. Pathology 2014, 46:95-104.
60. Vogelstein B., Papadopoulos N., Velculescu V.E., et al. Cancer genome landscapes. Science 2013, 339:1546-1558.
61. Ognjanovic S., Olivier M., Bergemann T.L., et al. Sarcomas in TP53 germline mutation carriers: a review of the IARC TP53 database. Cancer 2012, 118:1387-1396.
62. MacCarthy A., Bayne A.M., Brownbill P.A., et al. Second and subsequent tumours among 1927 retinoblastoma patients diagnosed in Britain 1951-2004. Br J Cancer 2013, 108:2455-2463.
63. Toguchida J., Ishizaki K., Sasaki M.S., et al. Preferential mutation of paternally derived RB gene as the initial event in sporadic osteosarcoma. Nature 1989, 338:156-158.
64. Chen X., Bahrami A., Pappo A., et al. Recurrent somatic structural variations contribute to tumorigenesis in pediatric osteosarcoma. Cell Rep 2014, 7:104-112.
65. Wunder J.S., Gokgoz N., Parkes R., et al. TP53 mutations and outcome in osteosarcoma: a prospective, multicenter study. J Clin Oncol 2005, 23:1483-1490.
66. van Oosterwijk J.G., Anninga J.K., Gelderblom H., et al. Update on targets and novel treatment options for high-grade osteosarcoma and chondrosarcoma. Hematol Oncol Clin North Am 2013, 27:1021-1048.
67. Hieken T.J., Das Gupta T.K. Mutant p53 expression: a marker of diminished survival in well-differentiated soft tissue sarcoma. Clin Cancer Res 1996, 2:1391-1395.
68. Hayden J.B., Hoang B.H. Osteosarcoma: basic science and clinical implications. Orthop Clin North Am 2006, 37:1-7.
69. Ito M., Barys L., O'Reilly T., et al. Comprehensive mapping of p53 pathway alterations reveals an apparent role for both SNP309 and MDM2 amplification in sarcomagenesis. Clin Cancer Res 2011, 17:416-426.
70. Ray-Coquard I., Blay J.Y., Italiano A., et al. Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients with MDM2-amplified, well-differentiated or dedifferentiated liposarcoma: an exploratory proof-of-mechanism study. Lancet Oncol 2012, 13:1133-1140.
71. Shangary S., Qin D., McEachern D., et al. Temporal activation of p53 by a specific MDM2 inhibitor is selectively toxic to tumors and leads to complete tumor growth inhibition. Proc Natl Acad Sci U S A 2008, 105:3933-3938.
72. Pishas K.I., Al-Ejeh F., Zinonos I., et al. Nutlin-3a is a potential therapeutic for Ewing sarcoma. Clin Cancer Res 2011, 17:494-504.
73. Frith A.E., Hirbe A.C., Van Tine B.A. Novel pathways and molecular targets for the treatment of sarcoma. Curr Oncol Rep 2013, 15:378-385.
74. Graves B., Thompson T., Xia M., et al. Activation of the p53 pathway by small-molecule-induced MDM2 and MDMX dimerization. Proc Natl Acad Sci U S A 2012, 109:11788-11793.
75. Hartmann C., Tabin C.J. Dual roles of Wnt signaling during chondrogenesis in the chicken limb. Development 2000, 127:3141-3159.
76. Hoang B.H. Wnt, osteosarcoma, and future therapy. J Am Acad Orthop Surg 2012, 20:58-59.
77. Cai Y., Mohseny A.B., Karperien M., et al. Inactive Wnt/beta-catenin pathway in conventional high-grade osteosarcoma. J Pathol 2010, 220:24-33.
78. Kansara M., Tsang M., Kodjabachian L., et al. Wnt inhibitory factor 1 is epigenetically silenced in human osteosarcoma, and targeted disruption accelerates osteosarcomagenesis in mice. J Clin Invest 2009, 119:837-851.
79. Mandal D., Srivastava A., Mahlum E., et al. Severe suppression of Frzb/sFRP3 transcription in osteogenic sarcoma. Gene 2007, 386:131-138.
80. Vijayakumar S., Liu G., Rus I.A., et al. High-frequency canonical Wnt activation in multiple sarcoma subtypes drives proliferation through a TCF/beta-catenin target gene, CDC25A. Cancer Cell 2011, 19:601-612.
81. Lin C.H., Ji T., Chen C.F., et al. Wnt signaling in osteosarcoma. Adv Exp Med Biol 2014, 804:33-45.
82. Yang Q., Guan K.L. Expanding mTOR signaling. Cell Res 2007, 17:666-681.
83. Brun J., Dieudonné F.X., Marty C., et al. FHL2 silencing reduces Wnt signaling and osteosarcoma tumorigenesis in vitro and in vivo. PLoS One 2013, 8:e55034.
84. Tao J., Jiang M.M., Jiang L., et al. Notch activation as a driver of osteogenic sarcoma. Cancer Cell 2014, 26:390-401.
85. Mu X., Isaac C., Greco N., et al. Notch signaling is associated with ALDH activity and an aggressive metastatic phenotype in murine osteosarcoma cells. Front Oncol 2013, 3:143.
86. Samuel A.M., Costa J., Lindskog D.M. Genetic alterations in chondrosarcomas - keys to targeted therapies?. Cell Oncol (Dordr) 2014, 37:95-105.
87. Lo W.W., Wunder J.S., Dickson B.C., et al. Involvement and targeted intervention of dysregulated Hedgehog signaling in osteosarcoma. Cancer 2014, 120:537-547.
88. Kelleher F.C., Cain J.E., Healy J.M., et al. Prevailing importance of the hedgehog signaling pathway and the potential for treatment advancement in sarcoma. Pharmacol Ther 2012, 136:153-168.
89. Martin J.W., Zielenska M., Stein G.S., et al. The Role of RUNX2 in osteosarcoma oncogenesis. Sarcoma 2011, 2011:282745.
90. Lahat G., Zhang P., Zhu Q.S., et al. The expression of c-Met pathway components in unclassified pleomorphic sarcoma/malignant fibrous histiocytoma (UPS/MFH): a tissue microarray study. Histopathology 2011, 59:556-561.
91. Scotlandi K., Baldini N., Oliviero M., et al. Expression of Met/hepatocyte growth factor receptor gene and malignant behavior of musculoskeletal tumors. Am J Pathol 1996, 149:1209-1219.
92. Wallenius V., Hisaoka M., Helou K., et al. Overexpression of the hepatocyte growth factor (HGF) receptor (Met) and presence of a truncated and activated intracellular HGF receptor fragment in locally aggressive/malignant human musculoskeletal tumors. Am J Pathol 2000, 156:821-829.
93. Patane S., Avnet S., Coltella N., et al. MET overexpression turns human primary osteoblasts into osteosarcomas. Cancer Res 2006, 66:4750-4757.
94. Wagner A.J., Goldberg J.M., Dubois S.G., et al. Tivantinib (ARQ 197), a selective inhibitor of MET, in patients with microphthalmia transcription factor-associated tumors: results of a multicenter phase 2 trial. Cancer 2012, 118:5894-5902.
95. Egas-Bejar D., Anderson P.M., Agarwal R., et al. Theranostic profiling for actionable aberrations in advanced high risk osteosarcoma with aggressive biology reveals high molecular diversity: the human fingerprint hypothesis. Oncoscience 2014, 1:167-179.
96. Wang Y.H., Han X.D., Qiu Y., et al. Increased expression of insulin-like growth factor-1 receptor is correlated with tumor metastasis and prognosis in patients with osteosarcoma. J Surg Oncol 2012, 105:235-243.
97. Krueger D.A., Care M.M., Holland K., et al. Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis. N Engl J Med 2010, 363:1801-1811.
98. Franz D.N., Belousova E., Sparagana S., et al. Everolimus for subependymal giant cell astrocytoma in patients with tuberous sclerosis complex: 2-year open-label extension of the randomised EXIST-1 study. Lancet Oncol 2014, 15:1513-1520.
99. Bissler J.J., Kingswood J.C., Radzikowska E., et al. Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet 2013, 381:817-824.
100. Pazdur R, et al. FDA Approval for everolimus. 2013. Available at: Accessed June 23, 2015. http://www.cancer.gov/about-cancer/treatment/drugs/fda-everolimus.
101. Demetri G.D., Chawla S.P., Ray-Coquard I., et al. Results of an international randomized phase III trial of the mammalian target of rapamycin inhibitor ridaforolimus versus placebo to control metastatic sarcomas in patients after benefit from prior chemotherapy. J Clin Oncol 2013, 31:2485-2492.
102. Rikhof B., de Jong S., Suurmeijer A.J., et al. The insulin-like growth factor system and sarcomas. J Pathol 2009, 217:469-482.
103. Steigen S.E., Schaeffer D.F., West R.B., et al. Expression of insulin-like growth factor 2 in mesenchymal neoplasms. Mod Pathol 2009, 22:914-921.
104. Cironi L., Riggi N., Provero P., et al. IGF1 is a common target gene of Ewing's sarcoma fusion proteins in mesenchymal progenitor cells. PLoS One 2008, 3:e2634.
105. Mora J., Rodríguez E., de Torres C., et al. Activated growth signaling pathway expression in Ewing sarcoma and clinical outcome. Pediatr Blood Cancer 2012, 58:532-538.
106. van de Luijtgaarden A.C., Versleijen-Jonkers Y.M., Roeffen M.H., et al. Prognostic and therapeutic relevance of the IGF pathway in Ewing's sarcoma patients. Target Oncol 2013, 8:253-260.
107. Sun Y., Gao D., Liu Y., et al. IGF2 is critical for tumorigenesis by synovial sarcoma oncoprotein SYT-SSX1. Oncogene 2006, 25:1042-1052.
108. Ayalon D., Glaser T., Werner H. Transcriptional regulation of IGF-I receptor gene expression by the PAX3-FKHR oncoprotein. Growth Horm IGF Res 2001, 11:289-297.
109. Makawita S., Ho M., Durbin A.D., et al. Expression of insulin-like growth factor pathway proteins in rhabdomyosarcoma: IGF-2 expression is associated with translocation-negative tumors. Pediatr Dev Pathol 2009, 12:127-135.
110. van de Luijtgaarden A.C., Roeffen M.H., Leus M.A., et al. IGF signaling pathway analysis of osteosarcomas reveals the prognostic value of pAKT localization. Future Oncol 2013, 9:1733-1740.
111. Kolb E.A., Kamara D., Zhang W., et al. Kamara D, Zhang W, R1507, a fully human monoclonal antibody targeting IGF-1R, is effective alone and in combination with rapamycin in inhibiting growth of osteosarcoma xenografts. Pediatr Blood Cancer 2010, 55:67-75.
112. Rainusso N., Wang L.L., Yustein J.T. The adolescent and young adult with cancer: state of the art-bone tumors. Curr Oncol Rep 2013, 15:296-307.
113. Stegmaier K., Wong J.S., Ross K.N., et al. Signature-based small molecule screening identifies cytosine arabinoside as an EWS/FLI modulator in Ewing sarcoma. PLoS Med 2007, 4:e122.
114. Erkizan H.V., Kong Y., Merchant M., et al. A small molecule blocking oncogenic protein EWS-FLI1 interaction with RNA helicase A inhibits growth of Ewing's sarcoma. Nat Med 2009, 15:750-756.
115. Grohar P.J., Woldemichael G.M., Griffin L.B., et al. Identification of an inhibitor of the EWS-FLI1 oncogenic transcription factor by high-throughput screening. J Natl Cancer Inst 2011, 103:962-978.
116. Gautreau A., Poullet P., Louvard D., et al. Ezrin, a plasma membrane-microfilament linker, signals cell survival through the phosphatidylinositol 3-kinase/Akt pathway. Proc Natl Acad Sci U S A 1999, 96:7300-7305.
117. Louvet-Vallee S. ERM proteins: from cellular architecture to cell signaling. Biol Cell 2000, 92:305-316.
118. Bretscher A., Edwards K., Fehon R.G. ERM proteins and merlin: integrators at the cell cortex. Nat Rev Mol Cell Biol 2002, 3:586-599.
119. Pujuguet P., Del Maestro L., Gautreau A., et al. Ezrin regulates E-cadherin-dependent adherens junction assembly through Rac1 activation. Mol Biol Cell 2003, 14:2181-2191.
120. Geissler K.J., Jung M.J., Riecken L.B., et al. Regulation of Son of sevenless by the membrane-actin linker protein ezrin. Proc Natl Acad Sci U S A 2013, 110:20587-20592.
121. Khanna C., Wan X., Bose S., et al. The membrane-cytoskeleton linker ezrin is necessary for osteosarcoma metastasis. Nat Med 2004, 10:182-186.
122. Hunter K.W. Ezrin, a key component in tumor metastasis. Trends Mol Med 2004, 10:201-204.
123. Yu Y., Davicioni E., Triche T.J., et al. The homeoprotein six1 transcriptionally activates multiple protumorigenic genes but requires ezrin to promote metastasis. Cancer Res 2006, 66:1982-1989.
124. Krishnan K., Bruce B., Hewitt S., et al. Ezrin mediates growth and survival in Ewing's sarcoma through the AKT/mTOR, but not the MAPK, signaling pathway. Clin Exp Metastasis 2006, 23:227-236.
125. Weng W.H., Ahlen J., Astrom K., et al. Prognostic impact of immunohistochemical expression of ezrin in highly malignant soft tissue sarcomas. Clin Cancer Res 2005, 11:6198-6204.
126. Carneiro A., Bendahl P.O., Åkerman M., et al. Ezrin expression predicts local recurrence and development of metastases in soft tissue sarcomas. J Clin Pathol 2011, 64:689-694.
127. Kim M.S., Cho W.H., Song W.S., et al. Prognostic significance of ezrin expression in pleomorphic malignant fibrous histiocytoma. Anticancer Res 2007, 27:1171-1178.
128. Huang H.Y., Li C.F., Fang F.M., et al. Prognostic implication of ezrin overexpression in myxofibrosarcomas. Ann Surg Oncol 2010, 17:3212-3219.
129. Soderstrom M., Palokangas T., Vahlberg T., et al. Expression of ezrin, Bcl-2, and Ki-67 in chondrosarcomas. APMIS 2010, 118:769-776.
130. Ogino W., Takeshima Y., Mori T., et al. High level of ezrin mRNA expression in an osteosarcoma biopsy sample with lung metastasis. J Pediatr Hematol Oncol 2007, 29:435-439.
131. Ferrari S., Zanella L., Alberghini M., et al. Prognostic significance of immunohistochemical expression of ezrin in non-metastatic high-grade osteosarcoma. Pediatr Blood Cancer 2008, 50:752-756.
132. Wang Z., He M.L., Zhao J.M., et al. Meta-analysis of associations of the ezrin gene with human osteosarcoma response to chemotherapy and prognosis. Asian Pac J Cancer Prev 2013, 14:2753-2758.
133. Mu Y., Zhang H., Che L., et al. Clinical significance of microRNA-183/Ezrin axis in judging the prognosis of patients with osteosarcoma. Med Oncol 2014, 31:821.
134. Ren L., Khanna C. Role of ezrin in osteosarcoma metastasis. Adv Exp Med Biol 2014, 804:181-201.
135. Bulut G., Hong S.H., Chen K., et al. Small molecule inhibitors of ezrin inhibit the invasive phenotype of osteosarcoma cells. Oncogene 2012, 31:269-281.
136. Schwertschlag U.S., Trepicchio W.L., Dykstra K.H., et al. Hematopoietic, immunomodulatory and epithelial effects of interleukin-11. Leukemia 1999, 13:1307-1315.
137. Li T.M., Wu C.M., Huang H.C., et al. Interleukin-11 increases cell motility and up-regulates intercellular adhesion molecule-1 expression in human chondrosarcoma cells. J Cell Biochem 2012, 113:3353-3362.
138. Lewis V.O., Ozawa M.G., Deavers M.T., et al. The interleukin-11 receptor alpha as a candidate ligand-directed target in osteosarcoma: consistent data from cell lines, orthotopic models, and human tumor samples. Cancer Res 2009, 69:1995-1999.
139. Aggarwal B.B., Kunnumakkara A.B., Harikumar K.B., et al. Signal transducer and activator of transcription-3, inflammation, and cancer: how intimate is the relationship?. Ann N Y Acad Sci 2009, 1171:59-76.
140. Chen C.L., Loy A., Cen L., et al. Signal transducer and activator of transcription 3 is involved in cell growth and survival of human rhabdomyosarcoma and osteosarcoma cells. BMC Cancer 2007, 7:111.
141. David D., Rajappan L.M., Balachandran K., et al. Prognostic significance of STAT3 and phosphorylated STAT3 in human soft tissue tumors - a clinicopathological analysis. J Exp Clin Cancer Res 2011, 30:56.
142. Wang X., Goldstein D., Crowe P.J., et al. Impact of STAT3 inhibition on survival of osteosarcoma cell lines. Anticancer Res 2014, 34:6537-6545.
143. Bendell J.C., Hong D.S., Burris H.A., et al. Phase 1, open-label, dose-escalation, and pharmacokinetic study of STAT3 inhibitor OPB-31121 in subjects with advanced solid tumors. Cancer Chemother Pharmacol 2014, 74:125-130.
144. Kim K.J., Li B., Winer J., et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 1993, 362:841-844.
145. Takahashi H., Shibuya M. The vascular endothelial growth factor (VEGF)/VEGF receptor system and its role under physiological and pathological conditions. Clin Sci (Lond) 2005, 109:227-241.
146. Lin C.Y., Hung S.Y., Chen H.T., et al. Brain-derived neurotrophic factor increases vascular endothelial growth factor expression and enhances angiogenesis in human chondrosarcoma cells. Biochem Pharmacol 2014, 91:522-533.
147. Wakamatsu T., Naka N., Sasagawa S., et al. Deflection of vascular endothelial growth factor action by SS18-SSX and composite vascular endothelial growth factor- and chemokine (C-X-C motif) receptor 4-targeted therapy in synovial sarcoma. Cancer Sci 2014, 105:1124-1134.
148. Katuri V., Gerber S., Qiu X., et al. WT1 regulates angiogenesis in Ewing Sarcoma. Oncotarget 2014, 5:2436-2449.
149. Miyoshi K., Kohashi K., Fushiujmi F., et al. Close correlation between CXCR4 and VEGF expression and frequent CXCR7 expression in rhabdomyosarcoma. Hum Pathol 2014, 45:1900-1909.
150. Yang J., Zhao L., Tian W., et al. Correlation of WWOX, RUNX2 and VEGFA protein expression in human osteosarcoma. BMC Med Genomics 2013, 6:56.
151. Itakura E., Yamamoto H., Oda Y., et al. Detection and characterization of vascular endothelial growth factors and their receptors in a series of angiosarcomas. J Surg Oncol 2008, 97:74-81.
152. Young R.J., Fernando M., Hughes D., et al. Angiogenic growth factor expression in benign and malignant vascular tumours. Exp Mol Pathol 2014, 97:148-153.
153. Kummar S., Allen D., Monks A., et al. Cediranib for metastatic alveolar soft part sarcoma. J Clin Oncol 2013, 31:2296-2302.
154. Agulnik M., Yarber J.L., Okuno S.H., et al. An open-label, multicenter, phase II study of bevacizumab for the treatment of angiosarcoma and epithelioid hemangioendotheliomas. Ann Oncol 2013, 24:257-263.
155. Graeven U., Andre N., Achilles E., et al. Serum levels of vascular endothelial growth factor and basic fibroblast growth factor in patients with soft-tissue sarcoma. J Cancer Res Clin Oncol 1999, 125:577-581.
156. Yoon S.S., Segal N.H., Olshen A.B., et al. Circulating angiogenic factor levels correlate with extent of disease and risk of recurrence in patients with soft tissue sarcoma. Ann Oncol 2004, 15:1261-1266.
157. van Oosterwijk J.G., Meijer D., van Ruler M.A., et al. Screening for potential targets for therapy in mesenchymal, clear cell, and dedifferentiated chondrosarcoma reveals Bcl-2 family members and TGFbeta as potential targets. Am J Pathol 2013, 182:1347-1356.
158. Hoffman A., Ghadimi M.P., Demicco E.G., et al. Localized and metastatic myxoid/round cell liposarcoma: clinical and molecular observations. Cancer 2013, 119:1868-1877.
159. Ho A.L., Vasudeva S.D., Laé M., et al. PDGF receptor alpha is an alternative mediator of rapamycin-induced Akt activation: implications for combination targeted therapy of synovial sarcoma. Cancer Res 2012, 72:4515-4525.
160. Llombart B., Monteagudo C., Sanmartín O., et al. Dermatofibrosarcoma protuberans: a clinicopathological, immunohistochemical, genetic (COL1A1-PDGFB), and therapeutic study of low-grade versus high-grade (fibrosarcomatous) tumors. J Am Acad Dermatol 2011, 65:564-575.
161. Walluks K., Chen Y., Woelfel C., et al. Molecular and clinicopathological analysis of dermatofibrosarcoma protuberans. Pathol Res Pract 2013, 209:30-35.
162. O'Brien K.P., Seroussi E., Dal Cin P., et al. Various regions within the alpha-helical domain of the COL1A1 gene are fused to the second exon of the PDGFB gene in dermatofibrosarcomas and giant-cell fibroblastomas. Genes Chromosomes Cancer 1998, 23:187-193.
163. Takagi S., Takemoto A., Takami M., et al. Platelets promote osteosarcoma cell growth through activation of the platelet-derived growth factor receptor-Akt signaling axis. Cancer Sci 2014, 105:983-988.
164. Rutkowski P., Van Glabbeke M., Rankin C.J., et al. Imatinib mesylate in advanced dermatofibrosarcoma protuberans: pooled analysis of two phase II clinical trials. J Clin Oncol 2010, 28:1772-1779.
165. Kasper B., Sleijfer S., Litière S., et al. Long-term responders and survivors on pazopanib for advanced soft tissue sarcomas: subanalysis of two European Organisation for Research and Treatment of Cancer (EORTC) clinical trials 62043 and 62072. Ann Oncol 2014, 25:719-724.
166. van der Graaf W.T., Blay J.Y., Chawla S.P., et al. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 2012, 379:1879-1886.
167. de Souza R.R., Oliveira I.D., del Giúdice Paniago M., et al. Investigation of IGF2, Hedgehog and fusion gene expression profiles in pediatric sarcomas. Growth Horm IGF Res 2014, 24:130-136.
168. Crozat A., Aman P., Mandahl N., et al. Fusion of CHOP to a novel RNA-binding protein in human myxoid liposarcoma. Nature 1993, 363:640-644.
169. Rodriguez R., Tornin J., Suarez C., et al. Expression of FUS-CHOP fusion protein in immortalized/transformed human mesenchymal stem cells drives mixoid liposarcoma formation. Stem Cells 2013, 31:2061-2072.
170. Kobos R., Nagai M., Tsuda M., et al. Combining integrated genomics and functional genomics to dissect the biology of a cancer-associated, aberrant transcription factor, the ASPSCR1-TFE3 fusion oncoprotein. J Pathol 2013, 229:743-754.
171. Reis H., Hager T., Wohlschlaeger J., et al. Mammalian target of rapamycin pathway activity in alveolar soft part sarcoma. Hum Pathol 2013, 44:2266-2274.
172. Charytonowicz E., Matushansky I., Doménech J.D., et al. PAX7-FKHR fusion gene inhibits myogenic differentiation via NF-kappaB upregulation. Clin Transl Oncol 2012, 14:197-206.
173. Bovee J.V., van den Broek L.J., Cleton-Jansen A.M., et al. Up-regulation of PTHrP and Bcl-2 expression characterizes the progression of osteochondroma towards peripheral chondrosarcoma and is a late event in central chondrosarcoma. Lab Invest 2000, 80:1925-1934.
174. van Oosterwijk J.G., Herpers B., Meijer D., et al. Restoration of chemosensitivity for doxorubicin and cisplatin in chondrosarcoma in vitro: BCL-2 family members cause chemoresistance. Ann Oncol 2012, 23:1617-1626.
175. Morii T., Ohtsuka K., Ohnishi H., et al. BH3 mimetics inhibit growth of chondrosarcoma-a novel targeted-therapy for candidate models. Anticancer Res 2014, 34:6423-6430.
176. Schöffski P. CREATE: Cross-tumoral Phase 2 With Crizotinib. ClinicalTrials.gov Identifier NCT01524926. Available at: Accessed July 28, 2015. https://clinicaltrials.gov/ct2/show/NCT01524926?term=nct01524926%26rank=1.
177. Chawla SP, Staddon AP, Baker LH, et al. Study of AP23573/MK-8669 (Ridaforolimus), A Mammalian Target of Rapamycin (mTOR) Inhibitor, in Participants With Advanced Sarcoma (MK-8669-018 AM1). ClinicalTrials.gov Identifier NCT00093080. Available at: Accessed July 28, 2015. https://clinicaltrials.gov/ct2/show/NCT00093080?term=NCT00093080%26rank=1.
178. Yoo C., Lee J., Rha S.Y., et al. Multicenter phase II study of everolimus in patients with metastatic or recurrent bone and soft-tissue sarcomas after failure of anthracycline and ifosfamide. Invest New Drugs 2013, 31(6):1602-1608.
179. Wagner L. Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory Sarcoma. ClinicalTrials.gov Identifier NCT01614795. Available at: Accessed July 28, 2015. https://clinicaltrials.gov/ct2/show/NCT01614795?term=nct01614795%26rank=1.
180. Schwartz GK, Tap WD, Qin LX, et al. Temsirolimus and Cixutumumab in Treating Patients With Locally Advanced, Metastatic, or Recurrent Soft Tissue Sarcoma or Bone Sarcoma. ClinicalTrials.gov Identifier NCT01016015. Available at: Accessed July 28, 2015. https://clinicaltrials.gov/ct2/show/NCT01016015?term=NCT01016015%26rank=1.
181. Weigel B. Cixutumumab in Treating Patients With Relapsed or Refractory Solid Tumors. ClinicalTrials.gov Identifier NCT00831844. Available at: Accessed July 28, 2015. https://clinicaltrials.gov/ct2/show/NCT00831844?term=NCT00831844%26rank=1.
182. Tap WD, Demetri G, Barnette P, et al. A Phase 2 Study of AMG 479 in Relapsed or Refractory Ewing's Family Tumor and Desmoplastic Small Round Cell Tumors. ClinicalTrials.gov Identifier NCT00563680. Available at: Accessed July 28, 2015. https://clinicaltrials.gov/ct2/show/NCT00563680?term=00563680%26rank=1.
183. Pappo AS, Patel SR, Crowley J, et al. A Study of R1507 in Patients With Recurrent or Refractory Sarcoma. ClinicalTrials.gov Identifier NCT00642941. Available at: Accessed July 28, 2015. https://clinicaltrials.gov/ct2/show/NCT00642941?term=00642941%26rank=1.
184. Judson I, Scurr M, Gardner K, et al. The Biological Activity of Cediranib (AZD2171) in Gastro-Intestinal Stromal Tumours(GIST). ClinicalTrials.gov Identifier NCT00385203. Available at: Accessed July 28, 2015. https://clinicaltrials.gov/ct2/show/NCT00385203?term=00385203%26rank=1.
185. Kummar S, Allen D, Monks A, et al. Phase II Study of Cediranib (AZD2171) in Patients With Alveolar Soft Part Sarcoma. ClinicalTrials.gov Identifier NCT00942877. Available at: Accessed July 28, 2015. https://clinicaltrials.gov/ct2/show/NCT00942877?term=00942877%26rank=1.
186. Agulnik M. Bevacizumab in Treating Patients With Angiosarcoma. ClinicalTrials.gov Identifier NCT00288015. Available at: Accessed July 28, 2015. https://clinicaltrials.gov/ct2/show/NCT00288015?term=00288015%26rank=1.
187. Baruchel S, Pappo A, Krailo M, et al. Trabectedin in Treating Young Patients With Recurrent or Refractory Soft Tissue Sarcoma or Ewing's Family of Tumors. ClinicalTrials.gov Identifier: NCT00070109. Available at: Accessed July 28, 2015. https://clinicaltrials.gov/ct2/show/NCT00070109?term=00070109%26rank=1.
188. Butrynski JE. Doxorubicin Hydrochloride or Trabectedin in Treating Patients With Previously Untreated Advanced or Metastatic Soft Tissue Sarcoma. ClinicalTrials.gov Identifier NCT01189253. Available at: Accessed July 28, 2015. https://clinicaltrials.gov/ct2/show/NCT01189253?term=NCT01189253%26rank=1.
189. Cesne A.L., Judson I., Maki R., et al. Trabectedin is a feasible treatment for soft tissue sarcoma patients regardless of patient age: a retrospective pooled analysis of five phase II trials. Br J Cancer 2013, 109(7):1717-1724.
190. Le Cesne A, Blay JY, Domont J, et al. Continuing vs Intermittent Trabectedin-regimen in Patients With Advanced Soft Tissue Sarcoma Experiencing Response or Stable Disease After the 6th Cycle (T-DIS). ClinicalTrials.gov Identifier: NCT01303094. Available at: Accessed July 28, 2015. https://clinicaltrials.gov/ct2/show/NCT01303094?term=01303094%26rank=1.
191. Grignani G. Imatinib in Patients With Desmoid Tumor and Chondrosarcoma (Basket 1). ClinicalTrials.gov Identifier: NCT00928525. Available at: Accessed July 28, 2015. https://clinicaltrials.gov/ct2/show/NCT00928525?term=grignani+imatinib%26rank=1.
192. Ugurel S., Mentzel T., Utikal J., et al. Neoadjuvant imatinib in advanced primary or locally recurrent dermatofibrosarcoma protuberans: a multicenter phase II DeCOG trial with long-term follow-up. Clin Cancer Res 2014, 20(2):499-510.
193. Sugiura H., Fujiwara Y., Ando M., et al. Multicenter phase II trial assessing effectiveness of imatinib mesylate on relapsed or refractory KIT-positive or PDGFR-positive sarcoma. J Orthop Sci 2010, 15(5):654-660.
194. Dickson M. PD0332991 in Patients With Advanced or Metastatic Liposarcoma. ClinicalTrials.gov Identifier: NCT01209598. Available at: Accessed July 28, 2015. https://clinicaltrials.gov/ct2/show/NCT01209598?term=NCT01209598%26rank=1.
195. Ebb D. Chemotherapy With or Without Trastuzumab in Treating Patients With Metastatic Osteosarcoma. ClinicalTrials.gov Identifier: NCT00023998. Available at: Accessed July 28, 2015. https://clinicaltrials.gov/ct2/show/NCT00023998?term=NCT00023998%26rank=1.
196. Von Mehren M, Demetri GD. S0505 Sorafenib in Treating Patients With Advanced Soft Tissue Sarcomas. ClinicalTrials.gov Identifier: NCT00217620. Available at: Accessed July 28, 2015. https://clinicaltrials.gov/ct2/show/NCT00217620?term=00217620%26rank=1.
197. Grignani G. Sorafenib in Relapsed High Grade Osteosarcoma. ClinicalTrials.gov Identifier: NCT00889057. Available at: Accessed July 28, 2015. https://clinicaltrials.gov/ct2/show/NCT00889057?term=NCT00889057%26rank=1.
198. Aglietta M. Phase II Open Label, Non-randomized Study of Sorafenib and Everolimus in Relapsed and Non-resectable Osteosarcoma (SERIO). ClinicalTrials.gov Identifier: NCT01804374. Available at: Accessed July 28, 2015. https://clinicaltrials.gov/ct2/show/NCT01804374?term=NCT01804374%26rank=1.
199. Sleijfer S, Ray-Coquard I, Papai Z, et al. Pazopanib In Patients With Relapsed Or Refractory Soft Tissue Sarcoma. ClinicalTrials.gov Identifier: NCT00297258. Available at: Accessed July 28, 2015. https://clinicaltrials.gov/ct2/show/NCT00297258?term=NCT00297258%26rank=1.